REG - IXICO plc - Contract Win

IXICOAnnouncement

27/02/2025 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250227:nRSa6159Ya&default-theme=true

RNS Number : 6159Y  IXICO plc  27 February 2025

IXICO PLC
 
("IXICO" or the "Company")

 

Contract Wins in Alzheimer's and Huntington's Disease

 

27 February 2025 - London, UK. IXICO plc (AIM: IXI, "IXICO" or "the Company")
a global leader in neuroscience imaging, using its AI-driven platform to help
advance therapy research in neurological disorders, today announces that it
has signed a new commercial contract for a global Alzheimer's Disease (AD)
imaging analysis with a leading biotechnology company, and secured an
additional project in Huntington's Disease (HD) with an existing partner.

 

The combined value of the new contracts is more than £0.5 million, which will
be recognised within a year, and increases the proportion of expected revenues
for FY25 now contracted.

 

The positive commercial momentum continues IXICO's successful execution of its
'Innovate, Lead, Scale' strategy to drive expansion and growth. The nature of
both agreements provides the potential for further revenues in the future.

 

New AD Contract

The AD contract is with a multinational biotechnology company, to provide
imaging reads and data analysis using the dataset from the Global Alzheimer's
Platform Foundation's groundbreaking Bio-Hermes-001 study, of which IXICO is a
partner.

 

Additional HD Contract

The US headquartered client that contracted the Company to conduct a Phase 2
HD clinical trial, as announced on 10 December 2024, has subsequently deepened
and extended its commercial partnership. Underlining IXICO's leading HD
imaging platform status, a new project is being undertaken using the 'IXIQ.Ai'
platform to reanalyse data from a previous Phase I clinical trial.

 

Bram Goorden, CEO of IXICO, commented: "The AD trial is a significant win for
IXICO in that it complements the Company's strategy of expanding neuroimaging
biomarker analysis for partners into the clinical diagnostics market. Both the
AD contract win, and new HD project, reflect the continued recognition of
IXICO as a global neuroimaging market leader with an unrivalled biomarker
technology advantage."

 

Ends

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the UK version of the EU
Market Abuse Regulation 596/2014 which is part of UK law by virtue of the
European Union (Withdrawal) Act 2018, as amended and supplemented from time to
time. Upon the publication of this announcement, this inside information is
now considered to be in the public domain.

 

 

Further information:

 

 IXICO plc                                                                  +44 (0) 20 3763 7499
 Bram Goorden, Chief Executive Officer Grant Nash, Chief Financial Officer
 Cavendish Capital Markets Limited (Nominated Adviser and Sole Broker)      +44 (0) 20 7220 0500
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks/Harriet Ward (Corporate Broking) Michael F Johnson / Tamar
 Cranford Smith (Sales)

 

About IXICO www.IXICO.com (http://www.ixico.com/)

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUNAARVSUUUUR